Alliance trial aims to improve outcomes in metastatic prostate cancer

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Five-treatment radiation regimen poised to become standard of care, phase III data show

Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

September 26, 2025

Vol.51 No.35

In Brief

City of Hope expands clinical trial access across U.S. with new national model

City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.

September 19, 2025

Vol.51 No.34

Alliance trial aims to improve outcomes in metastatic prostate cancer

YOU MAY BE INTERESTED IN

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Five-treatment radiation regimen poised to become standard of care, phase III data show

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

City of Hope expands clinical trial access across U.S. with new national model

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Renew today!

Subscriber content

Never miss an issue!

Login